Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Javier Bolaños-MeadeMehdi HamadaniJuan WuMonzr M Al MalkiMichael J MartensLyndsey RunaasHany ElmariahAndrew R RezvaniMahasweta GooptuKarilyn T LarkinBrian C ShafferNajla El JurdiAlison W LorenMelhem SolhAric C HallAmin M AlousiOmer H JamyMiguel-Angel PeralesJanny M YaoKristy ApplegateAmi Siddharth BhattLeslie S KeanYvonne A EfeberaRan ReshefWilliam ClarkNancy L DiFronzoEric S LeiferMary M HorowitzRichard J JonesShernan G Holtannull nullPublished in: The New England journal of medicine (2023)
Among patients undergoing allogeneic HLA-matched HSCT with reduced-intensity conditioning, GVHD-free, relapse-free survival at 1 year was significantly more common among those who received cyclophosphamide-tacrolimus-mycophenolate mofetil than among those who received tacrolimus-methotrexate. (Funded by the National Heart, Lung, and Blood Institute and others; BMT CTN 1703 ClinicalTrials.gov number, NCT03959241.).